XMD17-109

XMD17-109

CAT N°: 25448
Price:

From 49.00 41.65

XMD17-109 is a selective ERK5 inhibitor (IC50 = 0.162 µM in an enzyme assay).{42420} It is selective for ERK5 over a panel of more than 200 kinases, inhibiting only ERK5 with greater than 90% target occupancy at a concentration of 10 µM. XMD17-109 inhibits ERK5 phosphorylation (IC50 = 0.09 µM in HeLa cells) and decreases AP-1 transcriptional activity (EC50 = 4.2 µM).{42421} It also inhibits human recombinant LRRK2[G2019S], which contains a mutation that has been linked to Parkinson’s disease, with an IC50 value of 0.339 µM in an enzyme assay.{42420}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 11-cyclopentyl-2-[[2-ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dihydro-5-methyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
  • Correlated keywords
    • ERK5IN-1 ERK5IN1 ERK5-IN1 XMD17109 XMD-17109 ERK-5 AP1 LRRK-2 G2019S
  • Product Overview:
    XMD17-109 is a selective ERK5 inhibitor (IC50 = 0.162 µM in an enzyme assay).{42420} It is selective for ERK5 over a panel of more than 200 kinases, inhibiting only ERK5 with greater than 90% target occupancy at a concentration of 10 µM. XMD17-109 inhibits ERK5 phosphorylation (IC50 = 0.09 µM in HeLa cells) and decreases AP-1 transcriptional activity (EC50 = 4.2 µM).{42421} It also inhibits human recombinant LRRK2[G2019S], which contains a mutation that has been linked to Parkinson’s disease, with an IC50 value of 0.339 µM in an enzyme assay.{42420}

We also advise you